Whitney Shatz-Binder

Dr. Whitney Shatz-Binder


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2013 in Nature Biotechnology
Verified
Journal Article
Closed access
CSChristoph Spiess
Christoph Spiess
MMMark Merchant
Mark Merchant
AHArthur Huang
Arthur Huang
ZZZhong Zheng
Zhong Zheng
NYNai-Ying Yang
Nai-Ying Yang
JSJustin M Scheer
Justin M Scheer

1 November 2013 in mAbs
Verified
Journal Article
Open access
WSWhitney Shatz-Binder
Whitney Shatz-Binder
SCShan Chung
Shan Chung
BLBing Li
Bing Li
BMBrett Marshall
Brett Marshall
MTMax Tejada
Max Tejada
JSJustin M Scheer
Justin M Scheer
Knobs-into-holes is a well-validated heterodimerization technology for the third constant domain of an antibody. This technology has been used to produce a monovalent IgG for clinical development (onartuzumab) and multiple bispecific antibodies.1,2 The most advanced uses of this approach, however, have been limited to E. coli as an expression host to produce non-glycosylated antibodies. Here, we applied the technology to mammalian host expression systems to produce glycosylated, effector-function competent heterodimeric antibodies. In our mammalian host system, each arm is secreted as a heavy chain-light chain (H-L) fragment with either the knob or hole mutations to allow for preferential heterodimer formation in vitro with low levels of homodimer contaminants. Like full antibodies, the secreted H-L fragments undergo Fc glycosylation in the endoplasmic reticulum. Using a monospecific anti-CD20 antibody, we show that full antibody-dependent cell-mediated cytotoxicity (ADCC) activity can be retained in the ...

1 September 2013 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
CSChristoph Spiess
Christoph Spiess
JBJack Bevers
Jack Bevers
JJJanet Jackman
Janet Jackman
NCNancy Chiang
Nancy Chiang
GNGerald Nakamura
Gerald Nakamura
LWLawren C. Wu
Lawren C. Wu
Human bispecific antibodies have great potential for the treatment of human diseases. Although human IgG1 bispecific antibodies have been generated, few attempts have been reported in the scientific literature that extend bispecific antibodies to other human antibody isotypes. In this paper, we report our work expanding the knobs-into-holes bispecific antibody technology to the human IgG4 isotype. We apply this approach to generate a bispecific antibody that targets IL-4 and IL-13, two cytokines that play roles in type 2 inflammation. We show that IgG4 bispecific antibodies can be generated in large quantities with equivalent efficiency and quality and have comparable pharmacokinetic properties and lung partitioning, compared with the IgG1 isotype. This work broadens the range of published therapeutic bispecific antibodies with natural surface architecture and provides additional options for the generation of bispecific antibodies with differing effector functions through the use of different antibody isotypes.

10 February 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
EHEmily Holz
Emily Holz
MDMartine Darwish
Martine Darwish
DTDevin B. Tesar
Devin B. Tesar
WSWhitney Shatz-Binder
Whitney Shatz-Binder
Over the past few decades, the complexity of molecular entities being advanced for therapeutic purposes has continued to evolve. A main propellent fueling innovation is the perpetual mandate within the pharmaceutical industry to meet the needs of novel disease areas and/or delivery challenges. As new mechanisms of action are uncovered, and as our understanding of existing mechanisms grows, the properties that are required and/or leveraged to enable therapeutic development continue to expand. One rapidly evolving area of interest is that of chemically enhanced peptide and protein therapeutics. While a variety of conjugate molecules such as antibody–drug conjugates, peptide/protein–PEG conjugates, and protein conjugate vaccines are already well established, others, such as antibody–oligonucleotide conjugates and peptide/protein conjugates using non-PEG polymers, are newer to clinical development. This review will evaluate the current development landscape of protein-based chemical conjugates with special attention to considerations such as modulation of pharmacokinetics, safety/tolerability, and entry into difficult to access targets, as well as bioavailability. Furthermore, for the purpose of this review, the types of molecules discussed are divided into two categories: (1) therapeutics that are enhanced by protein or peptide bioconjugation, and (2) protein and peptide therapeutics that require chemical modifications. Overall, the breadth of novel peptide- or protein-based therapeutics moving through the pipeline each year supports a path forward for the pursuit of even more complex therapeutic strategies.

14 June 2016 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
WSWhitney Shatz-Binder
Whitney Shatz-Binder
PHPhilip E. Hass
Philip E. Hass
MMMary Mathieu
Mary Mathieu
HKHok Seon Kim
Hok Seon Kim
KLKim Leach
Kim Leach
RKRobert F. Kelley
Robert F. Kelley

1 August 2015 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Open access
PDF file
KGKapil Gadkar
Kapil Gadkar
CPCinthia V. Pastuskovas
Cinthia V. Pastuskovas
JCJennifer E. Le Couter
Jennifer E. Le Couter
JEJ. Michael Elliott
J. Michael Elliott
JZJianhuan Zhang
Jianhuan Zhang
JSJustin M. Scheer
Justin M. Scheer
Purpose: To design and select the next generation of ocular therapeutics, we performed a comprehensive ocular and systemic pharmacokinetic (PK) analysis of a variety of antibodies and antibody fragments, including a novel-designed bispecific antibody. Methods: Molecules were administrated via intravitreal (IVT) or intravenous (IV) injections in rabbits, and antibody concentrations in each tissue were determined by ELISA. A novel mathematical model was developed to quantitate the structure–PK relationship Results: After IVT injection, differences in vitreal half-life observed across all molecules ranged between 3.2 and 5.2 days. Modification or elimination of the fragment crystallizable (Fc) region reduced serum half-life from 9 days for the IgG to 5 days for the neonatal Fc receptor (FcRn) null mAb, to 3.1 to 3.4 days for the other formats. The F(ab')2 was the optimal format for ocular therapeutics with comparable vitreal half-life to full-length antibodies, but with minimized systemic exposure. Concomitantly, the consistency among mathematical model predictions and observed data validated the model for future PK predictions. In addition, we showed a novel design to develop bispecific antibodies, here with activity targeting multiple angiogenesis pathways. Conclusions: We demonstrated that protein molecular weight and Fc region do not play a critical role in ocular PK, as they do systemically. Moreover, the mathematical model supports the selection of the “ideal therapeutic” by predicting ocular and systemic PK of any antibody format for any dose regimen. These findings have important implications for the design and selection of ocular therapeutics according to treatment needs, such as maximizing ocular half-life and minimizing systemic exposure.